Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author HARO, Josep Maria
CORRAL, Ricardo
EVANS, Jonathan
KREBS, Marie-Odile
ZINK, Mathias
MALLA, Ashok
MENDEZ, Jose Ignacio
LALONDE, Justine
dc.date.issued 2018
dc.identifier.citation PSYCHIATRY RESEARCH, v.267, p.56-62, 2018
dc.identifier.issn 0165-1781
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29553
dc.description.abstract The Pattern study was conducted to provide longitudinal observational data for individual patients with persistent symptoms of schizophrenia. Pattern is an international, multicenter, non-interventional, prospective cohort study of schizophrenia outpatients who were not considered to be in recovery. In the longitudinal phase reported herein, patients were assessed over 1 year using different clinical rating scales. Patient management followed routine local clinical practice. Primary outcome was disease state, defined by the Positive and Negative Syndrome Scale (PANSS), Negative Symptom Factor Score (NSFS), Positive Symptom Factor Score (PSFS), and Personal and Social Performance (PSP) Scale. In total, 1344 protocol-compliant patients (70.9% male) were included. Patients showed a high stability in disease state between consecutive study visits. Persistent negative persistent symptoms and symptomatic remission were the most prevalent and stable disease states. Patients in relapse generally transitioned to negative persistent symptoms or to symptomatic remission. PANSS, PSP, and quality of life ratings remained relatively stable. Relapses occurred in 10% of patients; probability of relapse was associated with younger age, extra-pyramidal symptoms, and more antipsychotic medications. Despite treatment, schizophrenia symptoms tend to remain stable over time, without overall improvement. One of the greatest challenges in schizophrenia is attainment of full symptom remission.
dc.description.sponsorship · Bridge Medical
dc.language.iso eng
dc.relation.ispartof Psychiatry Research
dc.rights restrictedAccess
dc.subject Negative symptoms; Positive symptoms; Naturalistic; Remission; Recovery; Relapse
dc.subject.other outpatient health outcomes; treatment-resistant schizophrenia; quality-of-life; negative symptoms; schizoaffective disorder; 1st episode; follow-up; 1st-episode psychosis; placebo-response; remission
dc.title Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study
dc.type article
dc.rights.holder Copyright ELSEVIER IRELAND LTD
dc.identifier.doi 10.1016/j.psychres.2018.04.005
dc.identifier.pmid 29883861
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author ELKIS, Helio:FM:MPS
hcfmusp.author.external · HARO, Josep Maria:Univ Barcelona, CIBERSAM, Parc Sanitari St Joan de Deu, Barcelona, Spain
· ALTAMURA, Carlo:Univ Milan, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Via F Sforza 35, I-20122 Milan, Italy
· CORRAL, Ricardo:FETEM, Cervino 4634 5th Floor Apt B,C1425AHQ, Buenos Aires, DF, Argentina
· EVANS, Jonathan:Univ Bristol, Ctr Acad Mental Hlth, Bristol BS8 2BN, Avon, England
· KREBS, Marie-Odile:Univ Paris 05, Hop St Anne, Inserm, Serv Hosp Univ,Lab Physiopathol Malad Psychiat, Paris, France
· ZINK, Mathias:Heidelberg Univ, Bezirkskrankenhaus Ansbach, Med Fac Mannheim, Cent Inst Mental Hlth,Dept Psychiat & Psychothera, Mannheim, Germany
· MALLA, Ashok:McGill Univ, Montreal, PQ, Canada
· MENDEZ, Jose Ignacio:OXON Epidemiol, Madrid, Spain
· BERNASCONI, Corrado:F Hoffmann La Roche Ltd, Basel, Switzerland
· LALONDE, Justine:F Hoffmann La Roche Ltd, Basel, Switzerland
· NORDSTROEM, Anna-Lena:F Hoffmann La Roche Ltd, Basel, Switzerland
hcfmusp.origem.id WOS:000445983700009
hcfmusp.origem.id 2-s2.0-85048473765
hcfmusp.publisher.city CLARE
hcfmusp.publisher.country IRELAND
hcfmusp.relation.reference · Agid O, 2013, AM J PSYCHIAT, V170, P1335, DOI 10.1176/appi.ajp.2013.12030315
· American Psychiatric Association, 2000, DIAGN STAT MAN MENT
· Andreasen NC, 2005, AM J PSYCHIAT, V162, P441, DOI 10.1176/appi.ajp.162.3.441
· Buchanan RW, 2007, SCHIZOPHRENIA BULL, V33, P1013, DOI 10.1093/schbul/sbl057
· Cassidy CM, 2010, SCHIZOPHRENIA BULL, V36, P1001, DOI 10.1093/schbul/sbp007
· Chakos MH, 2006, PSYCHIAT SERV, V57, P1094, DOI 10.1176/appi.ps.57.8.1094
· Chang WC, 2011, SCHIZOPHR RES, V133, P22, DOI 10.1016/j.schres.2011.09.006
· Chue P, 2014, NEUROPSYCH DIS TREAT, V10, P777, DOI 10.2147/NDT.S43404
· Csernansky JG, 2002, CNS DRUGS, V16, P473, DOI 10.2165/00023210-200216070-00004
· Doering S, 1998, SCHIZOPHRENIA BULL, V24, P87, DOI 10.1093/oxfordjournals.schbul.a033316
· Dold Markus, 2015, Evid Based Ment Health, V18, P77, DOI 10.1136/eb-2015-102098
· Emsley R, 2011, CURR OPIN PSYCHIATR, V24, P114, DOI 10.1097/YCO.0b013e3283436ea3
· *EUROQOL GROUP, 1990, HLTH POLICY, V16, P199, DOI 10.1016/0168-8510(90)90421-9
· Fervaha G, 2014, ACTA PSYCHIAT SCAND, V130, P290, DOI 10.1111/acps.12289
· Fervaha G, 2014, EUR NEUROPSYCHOPHARM, V24, P1078, DOI 10.1016/j.euroneuro.2014.03.001
· Hafner H, 2015, WORLD J PSYCHIATR, V5, P167, DOI 10.5498/wjp.v5.i2.167
· Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P16, DOI 10.1034/j.1600-0447.107.s416.5.x
· Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P7, DOI 10.1034/j.1600-0447.107.s416.4.x
· Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P222, DOI 10.1034/j.1600-0447.2003.00064.x
· Harrow M, 2005, SCHIZOPHRENIA BULL, V31, P723, DOI 10.1093/schbul/sbi026
· HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409
· HOFFMANN H, 1994, ACTA PSYCHIAT SCAND, V89, P205, DOI 10.1111/j.1600-0447.1994.tb08093.x
· Iasevoli F, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.08.010
· Jaaskelainen E., 2015, SCHIZOPHR RES TREATM, V2015
· Jordan G, 2014, J CLIN PSYCHIAT, V75, pE566, DOI 10.4088/JCP.13m08606
· KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
· LIDDLE PF, 1987, PSYCHOL MED, V17, P49, DOI 10.1017/S0033291700012976
· MALLA AK, 1993, SCHIZOPHR RES, V10, P143, DOI 10.1016/0920-9964(93)90049-O
· Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205
· Haro JM, 2006, J CLIN PSYCHOPHARM, V26, P571, DOI 10.1097/01.jcp.0000246215.49271.b8
· Haro JM, 2015, SCHIZOPHR RES, V169, P234, DOI 10.1016/j.schres.2015.09.001
· McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001
· Menezes NM, 2006, PSYCHOL MED, V36, P1349, DOI 10.1017/S0033291706007951
· Milev P, 2005, AM J PSYCHIAT, V162, P495, DOI 10.1176/appi.ajp.162.3.495
· Morosini PL, 2000, ACTA PSYCHIAT SCAND, V101, P323, DOI 10.1111/j.1600-0447.2000.tb10933.x
· Norman RMG, 1999, AM J PSYCHIAT, V156, P400
· Norman RMG, 2001, BRIT J PSYCHIAT, V179, P340, DOI 10.1192/bjp.179.4.340
· Novick D, 2007, PSYCHOPHARMACOLOGY, V191, P1015, DOI 10.1007/s00213-007-0730-2
· Novick D, 2009, SCHIZOPHR RES, V108, P223, DOI 10.1016/j.schres.2008.11.007
· Owen MJ, 2016, LANCET, V388, P86, DOI 10.1016/S0140-6736(15)01121-6
· Rabinowitz J, 2012, SCHIZOPHR RES, V137, P147, DOI 10.1016/j.schres.2012.01.015
· Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241
· Robinson DG, 2004, AM J PSYCHIAT, V161, P473, DOI 10.1176/appi.ajp.161.3.473
· Rutherford BR, 2014, JAMA PSYCHIAT, V71, P1409, DOI 10.1001/jamapsychiatry.2014.1319
· San L, 2013, INT J PSYCHIAT CLIN, V17, P2, DOI 10.3109/13651501.2012.687452
· Stahl SM, 2004, CURR MED CHEM, V11, P313, DOI 10.2174/0929867043456070
· Strauss G.P., 2008, SCHIZOPHRENIA B, V36, P788
· Suzuki T, 2014, HUM PSYCHOPHARM CLIN, V29, P414, DOI 10.1002/hup.2421
· Suzuki T, 2012, PSYCHIAT RES, V197, P1, DOI 10.1016/j.psychres.2012.02.013
· Suzuki T, 2011, SCHIZOPHR RES, V133, P54, DOI 10.1016/j.schres.2011.09.016
· Tajima-Pozo Kazuhiro, 2015, F1000Res, V4, P182, DOI 10.12688/f1000research.6699.1
· Ventura J, 2015, SCHIZOPHR RES, V161, P407, DOI 10.1016/j.schres.2014.10.043
· Ventura J, 2011, SCHIZOPHR RES, V132, P18, DOI 10.1016/j.schres.2011.06.025
· White C, 2009, PSYCHOL MED, V39, P1447, DOI 10.1017/S003329170800514X
· Wilkinson G, 2000, BRIT J PSYCHIAT, V177, P42, DOI 10.1192/bjp.177.1.42
· World Health Organization, 2011, INT STAT CLASS DIS R
· Zink M, 2016, LANCET PSYCHIAT, V3, P310, DOI 10.1016/S2215-0366(16)00023-7
· Zink M, 2015, EXPERT REV CLIN PHAR, V8, P335, DOI 10.1586/17512433.2015.1040393
dc.description.index MEDLINE
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Argentina
hcfmusp.affiliation.country Inglaterra
hcfmusp.affiliation.country França
hcfmusp.affiliation.country Alemanha
hcfmusp.affiliation.country Canadá
hcfmusp.affiliation.country Suíça
hcfmusp.affiliation.country Itália
hcfmusp.affiliation.country Espanha

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account